This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(Currently amended)** An anticonvulsant pharmaceutical composition for nasal administration having a binding affinity for at least one receptor site selected from the group consisting of Gamma-Amino Butyric Acid (GABA)-A agonist site, Glutamate- alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) site, Glutamate-Kainate site, Glutamate-*N*-methyl-D-aspartic acid (NMDA) agonistic site, Glutamate-*N*-methyl-D-aspartic acid (NMDA) glycine (strychnine insensitive) site and Sodium channel (site 2), consisting essentially of:

i. an aqueous, alcoholic, or hydroalcoholic extract of the pericarp of the fruit of *Sapindus* (*S.*)*trifoliatus*, comprising from 0.001 to 1.0 (% w/v) of hederagenin, and

ii. at least one pharmaceutically acceptable additive.

2. **(Previously presented)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 1, wherein the extract comprises hederagenin in an amount from 0.004% to 0.08 (% w/v).

3. **(Original)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 1, wherein the said extract is in the form of a lyophilized powder or an aqueous solution.

4. **(Original)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 1, being suitable for prophylactic treatment of migraine, mediated through its anticonvulsant activity.

5. **(Previously presented)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 1 wherein the least one pharmaceutically acceptable additive is

Banner & Witcoff, Ltd
10 S. Wacker Drive, Suite 3000
Chicago, IL 60606
(312) 463-5000

selected from the group consisting of at least one preservative agent, at least one agent for adjusting the tonicity, at least one agent for adjusting viscosity, and at least one agent for adjusting pH.

6. **(Original)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 5 wherein the said agent for adjusting the tonicity, is sodium chloride.

7. **(Previously presented)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 5 wherein the said agent for adjusting the viscosity is selected from the group consisting of xanthan gum, carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, polyvinyl alcohol and carbomers.

8. **(Previously presented)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 5 wherein the said agent for adjusting the pH is selected from the group consisting of citric acid, sodium citrate, potassium dihydrogen phosphate, acetic acid, sodium acetate and ammonium acetate.

9. **(Previously presented)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 5 wherein the said preservative agent is selected from the group consisting of chlorbutanol, phenyl ethyl alcohol and parabens.

10. **(Previously presented)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 1 wherein the pH, is in the range of between 4.5-6.5.

11. **(Previously presented)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 1 wherein the said composition is in the form selected from the group consisting of nasal drops, nasal sprays, nasal powders, semisolid nasal preparations, nasal washes, and nasal sticks.

Banner & Witcoff, Ltd
10 S. Wacker Drive, Suite 3000
Chicago, IL 60606
(312) 463-5000

12. **(Previously presented)** A process for preparation of an extract comprising the steps of:

a. extraction of the pericarp of the fruit of *Sapindus (S.)trifoliatus* with water or an alcohol or a mixture thereof at ambient to boiling temperature for 0.5 to 24 hours,

b. lyophilization of the aqueous, alcoholic or aqueous alcoholic extract containing a mixture of saponins to give a lyophilized powder, containing a mixture of saponins, and

c. reconstitution of the lyophilized extract in water to achieve a concentration of hederagenin between 0. 001 to 1.0 (% w/v).

13. **(Original)** A process according to claim 12, wherein the alcohol is selected from a C_{1-4} alcohol.

14. **(Previously presented)** A process according to claim 12 wherein the C_{1-4} alcohol is selected from the group consisting of methanol, ethanol, n-propanol, iso-propanol, n-butanol, iso-butanol and tert- butanol.

15. **(Currently amended)** A process for preparation of an anticonvulsant pharmaceutical composition comprising:

i. adding lyophilized aqueous extract of *Sapindus (S.)trifoliatus* as formed in accordance with the process of claim 12 to a mixture of Chlorobutanol and Phenylethyl alcohol in water and sodium chloride, to get a uniform dispersion,
ii. filtering;
iii. mixing above dispersion with dispersion of Xanthan gum in purified water; and
iv. adjusting the pH between 4.5-6.5.

Banner & Witcoff, Ltd
10 S. Wacker Drive, Suite 3000
Chicago, IL 60606
(312) 463-5000

16. **(Currently amended)** A composition according to claim 1 which exhibits *in vitro* receptor binding affinity towards a receptor selected from the group consisting of Gamma-Amino Butyric Acid (GABA)-A agonistic site, Glutamate-*N*-methyl-D-aspartic acid (NMDA) agonistic site, Glutamate-*N*-methyl-D-aspartic acid (NMDA) Glycine (strychnine insensitive) site and sodium channel (site 2) which have mediatory role in anticonvulsant effect.

17. **(Previously presented)** A composition according to claim 1 wherein the *in vivo* anticonvulsant activity in rat in accordance with a Maximal Electroshock Seizure model is exhibited by nasal administration.

18. **(Previously presented)** A composition according to claim 17 wherein the anticonvulsant activity exhibited in the Maximal Electroshock Seizure model of rat by intra nasal route of administration is without loss of motor co-ordination in rat in the effective dose range.

19. **(Previously presented)** A method of prophylactic treatment of migraine through anticonvulsant activity of the pharmaceutical composition according to claim 1 by its administration through intranasal route.

20. **(Previously presented)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 1 wherein the composition comprises pharmaceutically acceptable additives comprising a preservative agent, an agent for adjusting tonicity, an agent for adjusting viscosity, and an agent for adjusting pH.

21. **(New)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 1, said composition having a binding affinity for Glutamate AMPA site.

22. **(New)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 1, said composition having a binding affinity for Glutamate-Kainate site.

Banner & Witcoff, Ltd
10 S. Wacker Drive, Suite 3000
Chicago, IL 60606
(312) 463-5000

23. **(New)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 1, said composition having a binding affinity for NMDA glycine (strychnine insensitive) site.

24. **(New)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 1, said composition having a binding affinity for Sodium channel (site 2).

25. **(New)** An anticonvulsant pharmaceutical composition, for nasal administration according to claim 1, said composition having a binding affinity for Glutamate chloride.